Drugs / CBX129801
CBX129801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01293461 | Apr 2011 → Aug 2012 | diabetic polyneuropathy, type 1 diabetes mellitus | Cebix Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01681290 | Oct 2012 → Nov 2014 | diabetic polyneuropathy | Cebix Incorporated | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBX129801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01293461 ↗ |
| Known as | Ersatta | “A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes...” NCT01681290 ↗ |
| Known as | Pegylated human c-peptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594533 ↗ |
| Modality | Peptide | “synthetic C-peptide” NCT01293461 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT01293461 ↗ |